Cargando…

DNA methylation status as a biomarker of anti‐epidermal growth factor receptor treatment for metastatic colorectal cancer

Anti‐epidermal growth factor receptor (EGFR) treatment is an effective option for metastatic colorectal cancer (CRC) treatment. However, there are few reliable biomarkers to predict the clinical response to anti‐EGFR treatment. We investigated the genome‐wide DNA methylation status in metastatic col...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ouchi, Kota, Takahashi, Shin, Yamada, Yasuhide, Tsuji, Shingo, Tatsuno, Kenji, Takahashi, Hidekazu, Takahashi, Naoki, Takahashi, Masanobu, Shimodaira, Hideki, Aburatani, Hiroyuki, Ishioka, Chikashi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2015
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4714671/ https://www.ncbi.nlm.nih.gov/pubmed/26426205 http://dx.doi.org/10.1111/cas.12827

Ejemplares similares

microRNA-193a-3p is specifically down-regulated and acts as a tumor suppressor in BRAF-mutated colorectal cancer
por: Takahashi, Hidekazu, et al.
Publicado: (2017)

Consensus molecular subtypes classification of colorectal cancer as a predictive factor for chemotherapeutic efficacy against metastatic colorectal cancer
por: Okita, Akira, et al.
Publicado: (2018)

A modified MethyLight assay predicts the clinical outcomes of anti‐epidermal growth factor receptor treatment in metastatic colorectal cancer
por: Ouchi, Kota, et al.
Publicado: (2022)

Phase II study of trifluridine/tipiracil (TAS-102) therapy in elderly patients with colorectal cancer (T-CORE1401): geriatric assessment tools and plasma drug concentrations as possible predictive biomarkers
por: Takahashi, Masanobu, et al.
Publicado: (2021)

The G8 screening tool enhances prognostic value to ECOG performance status in elderly cancer patients: A retrospective, single institutional study
por: Takahashi, Masahiro, et al.
Publicado: (2017)

Upper Arm Central Venous Port Implantation: A 6-Year Single Institutional Retrospective Analysis and Pictorial Essay of Procedures for Insertion
por: Shiono, Masatoshi, et al.
Publicado: (2014)

Antibiotics Improve the Treatment Efficacy of Oxaliplatin-Based but Not Irinotecan-Based Therapy in Advanced Colorectal Cancer Patients
por: Imai, Hiroo, et al.
Publicado: (2020)

Efficacy of modified FOLFOX6 chemotherapy for patients with unresectable pseudomyxoma peritonei
por: Hiraide, Sakura, et al.
Publicado: (2019)

BRAF and MEK Inhibitor Treatment for Metastatic Undifferentiated Sarcoma of the Spermatic Cord with BRAF V600E Mutation
por: Saijo, Ken, et al.
Publicado: (2022)

Functional Complementation Assay for 47 MUTYH Variants in a MutY-Disrupted Escherichia Coli Strain
por: Komine, Keigo, et al.
Publicado: (2015)

Efficacy and safety of gemcitabine plus docetaxel in Japanese patients with unresectable or recurrent bone and soft tissue sarcoma: Results from a single-institutional analysis
por: Takahashi, Masanobu, et al.
Publicado: (2017)

Phase II study of biweekly cetuximab plus mFOLFOX6 or mFOLFIRI as second-line treatment for metastatic colorectal cancer and exploratory analysis of associations between DNA methylation status and the efficacy of the anti-EGFR antibody: T-CORE1201
por: Takahashi, Shin, et al.
Publicado: (2023)

Depth of response may predict clinical outcome in patients with recurrent/metastatic head and neck cancer treated with pembrolizumab-containing regimens
por: Saijo, Ken, et al.
Publicado: (2023)

Altered gene expression due to aberrant DNA methylation correlates with responsiveness to anti‐EGFR antibody treatment
por: Otsuki, Yasufumi, et al.
Publicado: (2022)

Different impacts of TP53 mutations on cell cycle-related gene expression among cancer types
por: Sasaki, Keiju, et al.
Publicado: (2023)

Retrospective analysis on the clinical outcomes of recombinant human soluble thrombomodulin for disseminated intravascular coagulation syndrome associated with solid tumors
por: Ouchi, Kota, et al.
Publicado: (2018)

Antibiotic therapy augments the efficacy of gemcitabine-containing regimens for advanced cancer: a retrospective study
por: Imai, Hiroo, et al.
Publicado: (2019)

Tumor suppressor miR‐193a‐3p enhances efficacy of BRAF/MEK inhibitors in BRAF‐mutated colorectal cancer
por: Hiraide, Sakura, et al.
Publicado: (2021)

Reply to comments on “Efficacy of modified FOLFOX6 chemotherapy for patients with unresectable pseudomyxoma peritonei”
por: Hiraide, Sakura, et al.
Publicado: (2021)

Predictive factors for the efficacy of the second taxane treatment in patients with advanced cancer
por: Imai, Hiroo, et al.
Publicado: (2018)

Antibiotic Treatment Improves the Efficacy of Oxaliplatin-Based Therapy as First-Line Chemotherapy for Patients with Advanced Gastric Cancer: A Retrospective Study
por: Imai, Hiroo, et al.
Publicado: (2022)

Study protocol of the TRICOLORE trial: a randomized phase III study of oxaliplatin-based chemotherapy versus combination chemotherapy with S-1, irinotecan, and bevacizumab as first-line therapy for metastatic colorectal cancer
por: Komatsu, Yoshito, et al.
Publicado: (2015)

lncRNA HAR1B has potential to be a predictive marker for pazopanib therapy in patients with sarcoma
por: Yamada, Hideharu, et al.
Publicado: (2021)

lncRNA HAR1B has potential to be a predictive marker for pazopanib therapy in patients with sarcoma
por: Yamada, Hideharu, et al.
Publicado: (2021)

TP53 Signature Can Predict Pathological Response From Neoadjuvant Chemotherapy and Is a Prognostic Factor in Patients With Residual Disease
por: Takahashi, Shin, et al.
Publicado: (2023)

Association between serum ligands and the skin toxicity of anti-epidermal growth factor receptor antibody in metastatic colorectal cancer
por: Takahashi, Naoki, et al.
Publicado: (2015)

Phase I/II study of sequential therapy with irinotecan and S-1 for metastatic colorectal cancer
por: Yoshioka, T, et al.
Publicado: (2009)

Overexpression of DRAM enhances p53-dependent apoptosis
por: Takahashi, Masahiro, et al.
Publicado: (2013)

High throughput RNAi screening identifies ID1 as a synthetic sick/lethal gene interacting with the common TP53 mutation R175H
por: IMAI, HIROO, et al.
Publicado: (2014)

Inhibition of stearoyl-CoA desaturase 1 (SCD1) enhances the antitumor T cell response through regulating β-catenin signaling in cancer cells and ER stress in T cells and synergizes with anti-PD-1 antibody
por: Katoh, Yuki, et al.
Publicado: (2022)

Biochemical, biological and structural properties of romidepsin (FK228) and its analogs as novel HDAC/PI3K dual inhibitors
por: Saijo, Ken, et al.
Publicado: (2015)

Transcriptomic expression profiling identifies ITGBL1, an epithelial to mesenchymal transition (EMT)-associated gene, is a promising recurrence prediction biomarker in colorectal cancer
por: Matsuyama, Takatoshi, et al.
Publicado: (2019)

Clinical decisions by the molecular tumor board on comprehensive genomic profiling tests in Japan: A retrospective observational study
por: Shirota, Hidekazu, et al.
Publicado: (2022)

Transgenic expression of the N525S-tuberin variant in Tsc2 mutant (Eker) rats causes dominant embryonic lethality
por: Shiono, Masatoshi, et al.
Publicado: (2014)

A case of hyperprogressive disease following atezolizumab therapy for pulmonary pleomorphic carcinoma with epidermal growth factor receptor mutation
por: Oguri, Tomoyo, et al.
Publicado: (2021)

Potential responders to FOLFOX therapy for colorectal cancer by Random Forests analysis
por: Tsuji, S, et al.
Publicado: (2012)

Prognostic role of ERBB2, MET and VEGFA expression in metastatic colorectal cancer patients treated with anti-EGFR antibodies
por: Takahashi, Naoki, et al.
Publicado: (2016)

A Case of Guillain-Barré Syndrome and Stevens-Johnson Syndrome/Toxic Epidermal Necrosis Overlap After Pembrolizumab Treatment
por: Oguri, Tomoyo, et al.
Publicado: (2021)

A case of disseminated intravascular coagulation following tumour lysis syndrome due to small cell carcinoma of the lung
por: Takahashi, Saeko, et al.
Publicado: (2023)

Advanced colorectal cancer subtypes (aCRCS) help select oxaliplatin‐based or irinotecan‐based therapy for colorectal cancer
por: Takahashi, Shin, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_ns6i67h9cvedl8fdk7g6jep3v0